Top Story Today
The Cure That Killed: CAR-T's Autoimmune Dream Hits a Wall
Three patients died from runaway immune reactions in Novartis's autoimmune CAR-T program, forcing the company to freeze eight clinical trials across lupus, MS, and seven other diseases. Days later, Bristol Myers Squibb paused its own autoimmune CAR-T program. The culprit: a hyperinflammatory syndrome called IEC-HS, where the engineered T-cells triggered an immune spiral so severe the body attacked itself. The safety signal upends the risk-benefit math for an entire category. CAR-T's toxicity is tolerable when the alternative is terminal cancer, but asking a 35-year-old lupus patient to accept those same odds is a fundamentally different proposition.
Why it matters: Every company in autoimmune CAR-T, from Kyverna to Cabaletta to Cartesian, now faces harder questions from regulators, investors, and patients. The field isn't dead, but the timeline to first approvals just got significantly longer, and the entire risk-benefit framework for deploying potent oncology tools in chronic diseases needs to be rebuilt.
Read more →Oncology Shakeups
For the First Time, a Drug Beat Keytruda Head-to-Head in Lung Cancer
Akeso's bispecific antibody ivonescimab posted 30.8 months median overall survival versus 22.6 months for Keytruda in first-line PD-L1-positive lung cancer. That's an extra eight months of life and a 49% reduction in disease progression. The drug attacks tumors from two angles (blocking PD-1 and cutting off blood supply via VEGF) with a single molecule. The catch: the trial was China-only, and global confirmatory data won't land until 2027.
Read more →Roche's $570M ADC Bet Cut Death Risk 54% in Small Cell Lung Cancer
MediLink's Tam-Peli delivered 13.3 months median survival versus 9.4 months for standard chemo in relapsed SCLC, with a 59% tumor response rate compared to just 10% for the old guard. Roche licensed the drug for $570 million in January. The Phase 3 was China-only, so global trials are next.
Read more →GSK's ADC Nearly Doubled Survival in Relapsed Small Cell Lung Cancer
GSK reported 18.5 months median overall survival with its B7-H3-targeting ADC in relapsed SCLC, compared to 10.3 months on topotecan. That 54% reduction in death risk puts GSK on a collision course with Amgen's tarlatamab and Merck's ifinatamab deruxtecan in a space that was stagnant for decades.
Read more →FDA Approved AstraZeneca's Breast Cancer Pill After Its Own Experts Said No
An advisory committee voted 3-6 against camizestrant. The FDA overruled them and granted accelerated approval anyway, citing a 56% reduction in disease progression for breast cancer patients with a specific genetic escape mutation. It's only the latest in a rare string of agency overrides that could embolden future sponsors with borderline data.
Read more →Regulatory and Clinical Milestones
The First Drug Ever Approved for Alexander Disease Costs $1.14M a Year
Ionis's Zanvastro became the first treatment for Alexander disease, an ultra-rare brain disorder with roughly 500 documented cases in history. In trials, treated patients lost just 2.1% of gait speed versus a 35.4% decline in controls. The FDA's willingness to approve a drug for such a tiny population sends a signal to every rare disease developer in biotech.
Read more →Takeda's Narcolepsy Drug Swept Every Endpoint by Replacing the Missing Brain Signal
Oveporexton hit every primary and secondary endpoint in two Phase 3 narcolepsy trials, reducing cataplexy episodes by up to 89% and keeping patients awake nearly 20 minutes longer than placebo. It's the first drug to replace the orexin signal narcolepsy patients are actually missing, rather than masking symptoms with stimulants.
Read more →Companies in Crisis
Sarepta's Black Box, 500 Layoffs, and a Gene Therapy Franchise Unraveling
Sarepta added the FDA's most serious safety warning to Elevidys after two fatal liver failures, then separately cut 36% of its workforce. The gene therapy is now restricted to ambulatory Duchenne patients only, and the company is pivoting away from AAV gene therapy toward siRNA. A franchise that generated $898.7 million in net product revenue in 2025 is eroding fast.
Read more →Science and Discovery
A New CAR-T Worked in Patients Who Already Failed CAR-T
PeproMene Bio published Lancet data showing 7 of 9 lymphoma patients achieved complete responses with its BAFF-R-targeting CAR-T, including four who had already failed standard CD19 CAR-T. Zero relapses so far, with the longest response holding at 35 months. The sample size is tiny, but the signal in a population with dismal post-CAR-T salvage outcomes is hard to ignore.
Read more →GSK Is Building an mRNA Flu Vaccine to Cannibalize Its Own Product Line
GSK is pushing an mRNA flu vaccine into Phase 3 trials, directly threatening its own egg-based franchise that pulled in £303 million last year. The candidate targets both HA and NA proteins on the flu virus (a first for mRNA flu shots), and Phase 2 data showed stronger immune responses than licensed vaccines across all age groups.
Read more →